Med-tech spin-out achieves successful second investment round to drive growth
Guilford Street Laboratories, a university spin-out focused on the child health sector, has completed a follow on investment round.
The venture is a spin-out of University College London and in partnership with Great Ormond Street Hospital, but is based in Liverpool.
The latest deal was advised on by GS Verde Group. The funding round builds on the successful pre-seed investment Guilford Street Labs raised in 2024, which marked a significant milestone for the company.
The latest undisclosed investment raise demonstrates the exciting enterprise taking further steps to accelerate its journey and future growth.
Guilford Street Laboratories began its journey in child health and paediatrics. Implementing mass spectrometry, the team focused on identifying rare disease biomarkers to help diagnosis and monitoring globally.
Following a successful collaboration on a commercial project, colleagues Dr Tomas Baldwin, Prof Kevin Mills and Dr Wendy Heywood began to explore the opportunities for the company on a larger scale – which led to the establishment of Guilford Street Labs in October 2023.
The company began trading in January 2024, marking the start of a venture dedicated to advancing its proven techniques and expanding for future growth.
With more than 40 years of combined academic expertise, the team at Guilford Street Labs provide accurate and highly sensitive analysis of protein, lipid, and metabolite biomarkers.
The company’s focus spans across rare, cardiac, and neurodegenerative diseases through machine learning – driven mass spectrometry to support clients at all points of the clinical journey.
From diagnostics, trials, and drug discovery, the business enhances patient care by serving some of the UK’s largest bio-pharma and gene therapy companies.
Under the leadership of CEO Dr Tomas Baldwin, CSO Prof Kevin Mills, and bioanalysis director Dr Wendy Heywood, the founding values of Guilford Street Labs are at the core of its services, with the company remaining committed to transforming diagnostic testing and redefining the future of healthcare.
CEO Dr Tomas Baldwin, said: “The support from both our new and existing investors has been remarkable.
“This milestone positions us strongly to accelerate advancements across our diagnostic programmes in hypertrophic cardiomyopathy and Parkinson’s disease.
“We would also like to thank the GS Verde team, whose support significantly streamlined the fundraising process. We look forward to continuing our successful collaboration.”
